دورية أكاديمية
أعرض في EDS

Evaluation of BCG Vaccination and Plasma Amyloid: A Prospective, Pilot Study with Implications for Alzheimer's Disease.

التفاصيل البيبلوغرافية
العنوان: Evaluation of BCG Vaccination and Plasma Amyloid: A Prospective, Pilot Study with Implications for Alzheimer's Disease.
المؤلفون: Dow CT; Department of Ophthalmology and Visual Sciences, McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, WI 53706, USA.; Mindful Diagnostics and Therapeutics, Eau Claire, WI 54701, USA., Greenblatt CL; Department of Microbiology and Molecular Genetics, Hebrew University, Jerusalem 9103401, Israel., Chan ED; Department of Academic Affairs, National Jewish Health, Denver, CO 80218, USA.; Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80217, USA.; Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO 80045, USA., Dow JF; Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.; Northwestern Wisconsin Region Mayo Clinic Health System, Eau Claire, WI 54703, USA.
المصدر: Microorganisms [Microorganisms] 2022 Feb 12; Vol. 10 (2). Date of Electronic Publication: 2022 Feb 12.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101625893 Publication Model: Electronic Cited Medium: Print ISSN: 2076-2607 (Print) Linking ISSN: 20762607 NLM ISO Abbreviation: Microorganisms Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: BCG vaccine has been used for 100 years to prevent tuberculosis. Not all countries, including the United States, adopted the initial World Health Organization recommendation to use BCG. Moreover, many Western countries that had routinely used BCG have discontinued its use. Recent population studies demonstrate lower prevalence of Alzheimer's disease (AD) in countries with high BCG coverage. Intravesicular instillation of BCG is also used to treat bladder cancer that has not invaded the bladder muscle wall and has been shown to reduce recurrence. Several retrospective studies of bladder cancer patients demonstrated that BCG treatment was associated with a significantly reduced risk of developing AD. Plasma amyloid β assessment has become a fertile area of study for an AD biomarker that is predictive of a positive amyloid PET scan. Mass spectrometry-based plasma amyloid 42/40 ratio has proven to be accurate and robust, and when combined with age and ApoE, is shown to accurately predict current and future brain amyloid status. These parameters, amyloid 42/40 ratio, age and ApoE genotype are incorporated into an Amyloid Probability Score (APS)-a score that identifies low, intermediate or high risk of having a PET scan positive for cerebral amyloid. Community recruitment was used for this open-label pilot study. Forty-nine BCG-naïve, immunocompetent individuals completed our study: prior to BCG prime and boost, as determined by the APS, 34 had low risk (APS 0-35), 5 had intermediate risk (APS 36-57) and 10 had high risk (APS 58-100). The APS range for the participant group was 0 to 94. Follow-up plasma amyloid testing 9 months after vaccination revealed a reduction in the APS in all the risk groups: low risk group ( p = 0. 37), intermediate risk group ( p = 0.13) and the high-risk group (statistically significant, p = 0.016). Greater benefit was seen in younger participants and those with the highest risk. The small number of participants and the nascent status of plasma amyloid testing will rightfully temper embracement of these results. However, both the favorable direction of change after BCG as well as the utility of the APS-a valuable surrogate AD biomarker-may prompt a definitive large-scale multicenter investigation of BCG and AD risk as determined by plasma amyloid peptide ratios and APS.
References: Neurology. 2019 Oct 22;93(17):e1647-e1659. (PMID: 31371569)
Front Immunol. 2021 Aug 05;12:692729. (PMID: 34421902)
NPJ Vaccines. 2021 Nov 30;6(1):143. (PMID: 34848711)
J Am Geriatr Soc. 2021 Dec 12;:. (PMID: 34897645)
Lancet Infect Dis. 2006 Mar;6(3):162-70. (PMID: 16500597)
Clin Infect Dis. 2018 Sep 28;67(8):1256-1261. (PMID: 29584893)
Virus Res. 2011 May;157(2):175-9. (PMID: 20869407)
Neurology. 2014 Jan 7;82(1):41-8. (PMID: 24306002)
Cancer Immunol Immunother. 2006 Aug;55(8):981-6. (PMID: 16333622)
Proc R Soc Med. 1931 Sep;24(11):1481-90. (PMID: 19988326)
Clin Chim Acta. 2021 Aug;519:267-275. (PMID: 34015303)
J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):1436-1443. (PMID: 33856020)
J Infect Dis. 2013 Aug 15;208(4):564-72. (PMID: 23661800)
J Infect Dis. 2018 Jul 24;218(5):679-687. (PMID: 29635431)
J Immunol. 2008 Nov 1;181(9):6201-12. (PMID: 18941210)
Front Immunol. 2021 Aug 05;12:714179. (PMID: 34421917)
PLoS One. 2014 May 07;9(5):e96779. (PMID: 24804776)
Tuberculosis (Edinb). 2001;81(1-2):133-9. (PMID: 11463234)
Alzheimers Res Ther. 2019 Apr 22;11(1):34. (PMID: 31010420)
J Exp Med. 2022 Feb 7;219(2):. (PMID: 34889942)
Tuber Lung Dis. 1994 Oct;75(5):348-52. (PMID: 7841428)
Curr Opin Immunol. 2018 Dec;55:89-96. (PMID: 30447407)
Neurobiol Dis. 2017 May;101:27-39. (PMID: 28189498)
Med Hypotheses. 2019 Feb;123:95-97. (PMID: 30696606)
Clin Microbiol Infect. 2019 Dec;25(12):1473-1478. (PMID: 31055165)
J Clin Immunol. 2003 Jul;23(4):247-57. (PMID: 12959217)
Acta Neuropathol. 2011 Feb;121(2):171-81. (PMID: 21170538)
PLoS One. 2012;7(8):e41756. (PMID: 22905105)
Microorganisms. 2021 Oct 09;9(10):. (PMID: 34683441)
Metabolism. 2017 Apr;69S:S41-S49. (PMID: 28129888)
Oncotarget. 2016 Oct 25;7(43):69347-69357. (PMID: 27713140)
PLoS One. 2019 Nov 7;14(11):e0224433. (PMID: 31697701)
JAMA Neurol. 2019 Jul 15;:. (PMID: 31305929)
Clin Transl Immunology. 2020 Dec 09;9(12):e1227. (PMID: 33318797)
Front Immunol. 2019 Feb 19;10:234. (PMID: 30837992)
Trans R Soc Trop Med Hyg. 1976;70(5-6):449-57. (PMID: 841647)
PLoS One. 2021 Nov 17;16(11):e0257405. (PMID: 34788293)
J Gen Virol. 2011 Dec;92(Pt 12):2746-2756. (PMID: 21813708)
J Alzheimers Dis. 2009;17(1):91-103. (PMID: 19494434)
Alzheimers Dement. 2016 Dec;12(12):1226-1234. (PMID: 27436677)
Cells. 2021 Nov 15;10(11):. (PMID: 34831403)
Alzheimers Res Ther. 2021 Dec 14;13(1):199. (PMID: 34906229)
Microorganisms. 2020 Feb 05;8(2):. (PMID: 32033287)
Nat Rev Immunol. 2016 Jun;16(6):392-400. (PMID: 27157064)
JAMA. 2015 May 19;313(19):1924-38. (PMID: 25988462)
J Alzheimers Dis. 2018;61(3):939-945. (PMID: 29254081)
فهرسة مساهمة: Keywords: Alzheimer’s; Alzheimer’s biomarker; BCG; Bacillus Calmette–Guérin; CD4:CD8; CMV; amyloid 42/40; amyloid probability score (APS); immune risk profile; non-specific effects of vaccines; plasma amyloid
تواريخ الأحداث: Date Created: 20220225 Latest Revision: 20220301
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8880735
DOI: 10.3390/microorganisms10020424
PMID: 35208878
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-2607
DOI:10.3390/microorganisms10020424